Oncology

Researchers investigated whether heavy alcohol consumption in early life was associated with high-grade prostate cancer in adulthood.

Women who carry the BRCA1 and BRCA2 gene mutations are at an increased risk of breast and ovarian cancer, yet many women are unaware of their mutation status.

A recent study discovered a new way to use bioinformatics to determine how a patient’s immune system responds to immunotherapy.

Improved access to uniform cancer care in rural areas could help reduce disparities seen between rural and urban patients.

"I’m always working on making things better for the patients. Chemotherapy can be quite a scary kind of treatment."

Nanoparticles that act as an ‘on and off’ switch could help improve the safety and efficacy of CAR T-cell therapy.

Officials with the FDA have expanded the indication of pembrolizumab (Keytruda, Merck) for patients with metastatic, non-squamous non-small cell lung cancer.

Officials with the FDA have expanded the indication of pembrolizumab (Keytruda, Merck) for patients with metastatic, non-squamous non-small cell lung cancer (NSqNSCLC).

Pembrolizumab in combination with chemotherapy reduced the risk of death by half in patients with metastatic, non-squamous non-small cell lung cancer compared with chemotherapy alone.

A look at last week's top stories in the world of pharmacy.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Lenvatinib (Lenvima) has been granted approval by the FDA as a first-line treatment for patients with unresectable hepatocellular carcinoma.

Surviving cancer during childhood can lead to health problems and depression later in life.

A liquid biopsy test examines circulating tumor cells in blood samples of patients with prostate cancer to determine how they will respond to certain therapies.

Researchers have developed a novel peptide drug called FFW that could potentially reduce tumor growth and slow progression of liver cancer.

Patients who were more satisfied with the communication they received from cancer care providers often had better health outcomes at lower costs.

Researchers have developed a novel peptide drug that has the potential to reduce tumor growth and slow down the spread of cancer cells.

Globally, lung cancer mortality rates among women are projected to increase by 43% from 2015 to 2030.

The annual cost of treating cancer is projected to rise to $173 billion by 2020, a 39% increase since 2010.

Nancy Egerton, PharmD, BCOP, discusses the pharmacist's role in oncology care.

Combination of Lenvima and Keytruda awarded second Breakthrough Therapy designation for the treatment of endometrial carcinoma.

Advancements in breast cancer treatment have improved survival rates, but financial hardships related to the cost of these lifesaving therapies can weigh heavily on patients.

Survey findings indicate that patients with breast cancer worry about financial hardships related to their treatment, yet many do not feel providers adequately address these concerns.

Study investigates complementary medicine use in patients with curable cancer types and its impact on survival and adherence to conventional therapy.

Top news of the day from across the health care landscape.

A recent systematic review and meta-analysis found that men with advanced cancers respond better than women to treatment with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors.

The approval of ivosidenib fills an unmet need for patients with relapsed or refractory acute myeloid leukemia who have an IDH1 genetic mutation.

Genentech announced that the FDA has granted Breakthrough Therapy Designation to atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) as a first-line treatment for patients with the most common form of liver cancer.